# MANGROVE (NCT04002297)

> A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04002297
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: BeOne Medicines
- Conditions: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
- Interventions: zanubrutinib; bendamustine; rituximab
- Enrollment: 510
- Primary outcome: Progression-free survival (PFS) determined by independent central review

## Commentary we found

- YouTube: 14
- Podcasts: 10
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=mangrove-nct04002297

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04002297", "email": "<work email>"}; the inbox owner confirms by the emailed link.